Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Charina Ortega"'
Autor:
Benjamin H. Weinberg, Jang Hwan Cho, Yash Agarwal, N. T. Hang Pham, Leidy D. Caraballo, Maciej Walkosz, Charina Ortega, Micaela Trexler, Nathan Tague, Billy Law, William K. J. Benman, Justin Letendre, Jacob Beal, Wilson W. Wong
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-10 (2019)
The availability of high performance recombinases with low basal activity and high dynamic range is limited. Here the authors present a library of over 20 orthogonal split recombinases that can be induced by small molecules, light and temperature in
Externí odkaz:
https://doaj.org/article/2d4222928cd84b6aa52fbca43ee615fa
Autor:
Andrew D. Griffiths, Alexei Godina, Guillaume Mottet, Gaël A. Millot, Bingqing Shen, Samantha N. Stewart, Vera Menrath, Sosthene Essono, Baptiste Saudemont, Clément Nizak, Annabelle Gérard, Antoine Sautel-Caillé, Scott McNamara, Matthieu Delince, Sami Ellouze, Jean Baudry, Marcel Reichen, Pablo Canales-Herrerias, Charina Ortega, Patrick England, Carlos Castrillon, Odile Richard-Le Goff, Colin Brenan, Klaus Eyer, Pascaline Mary, Luis Briseño-Roa, Allan Jensen, Pierre Bruhns, Raphael Clement Li-Ming Doineau, Adam Woolfe, Roshan Kumar, Bin Jia, Bruno Iannascoli, Yannick Pousse, Kevin Grosselin, Gregory Rose, Adeline Poitou
Publikováno v:
Nature Biotechnology
Nature Biotechnology, 2020, 38, pp.715-721. ⟨10.1038/s41587-020-0466-7⟩
Nature Biotechnology, Nature Publishing Group, 2020, pp.715-721. ⟨10.1038/s41587-020-0466-7⟩
Nature Biotechnology, 38
Nature Biotechnology, 2020, 38, pp.715-721. ⟨10.1038/s41587-020-0466-7⟩
Nature Biotechnology, Nature Publishing Group, 2020, pp.715-721. ⟨10.1038/s41587-020-0466-7⟩
Nature Biotechnology, 38
International audience; Mining the antibody repertoire of plasma cells and plasmablasts could enable the discovery of useful antibodies for therapeutic or research purposes1. We present a method for high-throughput, single-cell screening of IgG-secre
Autor:
Samantha N. Stewart, Annabelle Gérard, Bingqing Shen, Colin Brenan, Pascaline Mary, Matthieu Delince, Scott McNamara, Klaus Eyer, Guillaume Mottet, Sami Ellouze, Pierre Bruhns, Adam Woolfe, Pablo Canales-Herrerias, Charina Ortega, Antoine Sautel-Caillé, Carlos Castrillon, Raphael Clement Li-Ming Doineau, Jean Baudry, Allan Jensen, Odile Richard-Le Goff, Clément Nizak, Bruno Iannascoli, Vera Menrath, Gregory Rose, Adeline Poitou, Luis Briseño-Roa, Yannick Pousse, Bin Jia, Roshan Kumar, Marcel Reichen, Baptiste Saudemont, Alexei Godina, Patrick England, Kevin Grosselin, Gaël A. Millot, Sosthene Essono, Andrew D. Griffiths
Publikováno v:
Nature biotechnology. 38(6)
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Autor:
Sami Ellouze, Charina Ortega, Wenhua Xu, Xing Cai, Alexandra Staskus, Zhiyuan Wang, Jinping Gan, Liang Schweizer, Zachary Duda, Carine George, Sophie Foulon, Rebecca Silver, Juliana Crivello, Nicola Beltraminelli, Francisco Adrian, Shuo Wei, Jennifer Watkins-Yoon, Andreas Raue, Qian Zhang, Yun-Yueh Lu, Dean Lee, Mingjie Chen, Monika Manne, Ross B. Fulton, He Zhou
Publikováno v:
Cancer Research. 81:1883-1883
Despite the success of immune check point inhibition, identification of other pathways capable of modulating the immune response against the tumor remains challenging. T-cell co-stimulation has been investigated with limited clinical success so far d
Autor:
Ross B. Fulton, Zhiyuan Wang, Rebecca Silver, Ruina Jin, Joyce Pi, Jinping Gan, Zachery Duda, Andreas Raue, Monika Manne, Yuan Wang, Hongkai Zhang, Wenhua Xu, Xing Cai, Francisco Adrian, Carine George, Yun-Yueh Lu, Sophie Foulon, Sami Ellouze, Dean Lee, Charina Ortega, Robert Petit, Liang Schweizer, Julianna Crivello, Alexandra Staskus, Nicola Beltraminelli
Publikováno v:
Cancer Research. 81:1882-1882
Agonist OX40 antibodies have shown promising pre-clinical activities, but their clinical activities have been limited thus far. Several reasons may account for this limited clinical activity, including sub-optimal antibody design, dose selection, and
Autor:
Ross B. Fulton, Julianna Crivello, Francisco Adrian, Zachary Duda, Dean Lee, Charina Ortega, Roshan Kumar, Liang Schweizer, Matt Delince, Monika Manne, Andreas Raue, Alexandra Staskus
Publikováno v:
Cancer Research. 80:PO-048
Immunomodulatory antibodies such as checkpoint inhibitors are showing very promising results in the clinic, but only a minority of patients respond to treatment and it is still challenging to identify these subpopulations. Prospective identification
Autor:
Jia Wu, Andreas Raue, Ouyang Li, Zachary Duda, Ross B. Fulton, Alexandra Staskus, Pascaline Mary, Charina Ortega, Ruina Jin, Francisco Adrian, Mingfang Feng, Qian Zhang, Juliana Crivello, Joyce Pi, Nicola Beltraminelli, Matthieu Delince, Hongkai Zhang, Yuan Wang, Yun-Yueh Lu, Minmin Lu, Surendar Arumugam, Liang Schweizer
Publikováno v:
Cancer Research. 80:2285-2285
Agonistic antibodies against the co-stimulatory receptor OX-40 have shown promising activity in preclinical models, but clinical activity has only been observed in isolated cases. While co-stimulation of T cells is described as the primary pharmacolo
Autor:
Dean Lee, Juying Li, Roshan Kumar, He Zhou, Shuo Wei, Francisco Adrian, Charina Ortega, Stephanie Beq, Nicola Beltraminelli, Pascaline Mary, Liang Schweizer, Greg Rose, Qian Zhang, Guang Yang, Matthieu Delince
Publikováno v:
Cancer Research. 80:2282-2282
TNFR2 has recently emerged as a promising therapeutic target for Immuno-Oncology. TNFR2 expression on regulatory and effector T cells in the tumor microenvironment has been associated with T cell exhaustion and resistance to immune-checkpoint blockad